| First Author | Le TT | Year | 2014 |
| Journal | PLoS One | Volume | 9 |
| Issue | 1 | Pages | e87179 |
| PubMed ID | 24475249 | Mgi Jnum | J:212710 |
| Mgi Id | MGI:5582010 | Doi | 10.1371/journal.pone.0087179 |
| Citation | Le TT, et al. (2014) Uridine prevents fenofibrate-induced fatty liver. PLoS One 9(1):e87179 |
| abstractText | Uridine, a pyrimidine nucleoside, can modulate liver lipid metabolism although its specific acting targets have not been identified. Using mice with fenofibrate-induced fatty liver as a model system, the effects of uridine on liver lipid metabolism are examined. At a daily dosage of 400 mg/kg, fenofibrate treatment causes reduction of liver NAD(+)/NADH ratio, induces hyper-acetylation of peroxisomal bifunctional enzyme (ECHD) and acyl-CoA oxidase 1 (ACOX1), and induces excessive accumulation of long chain fatty acids (LCFA) and very long chain fatty acids (VLCFA). Uridine co-administration at a daily dosage of 400 mg/kg raises NAD(+)/NADH ratio, inhibits fenofibrate-induced hyper-acetylation of ECHD, ACOX1, and reduces accumulation of LCFA and VLCFA. Our data indicates a therapeutic potential for uridine co-administration to prevent fenofibrate-induced fatty liver. |
